Articles & Blogs

Perspectives on Anti-Infective Drug Development from Experts in the Trenches

A scientist working in a lab

Recent Articles & Blogs

Blog
Article
Building a leader in infectious diseases, Ankit Mahadevia, President and CEO, Spero Therapeutics
By:
Biotech 2050 Podcast:
July 13, 2021
July 21, 2024
Read more
Blog
Article
PASTEUR Act Reintroduced - A Bold, Potentially Transformative Approach to Addressing the Threat of Antimicrobial Resistance
By:
Cristina Larkin and David Melnick, MD
June 17, 2021
July 21, 2024
Read more
Blog
Article
Comprehensive Policy for Infection: There Has Never Been a Better Time
By:
Timmerman Report
March 24, 2021
July 21, 2024
Read more
Blog
Article
Getting Ready for the Next Pandemic with a Comprehensive Response
By:
Timmerman Report
November 5, 2020
July 21, 2024
Read more
Blog
Article
Playing To Win: Scenario Planning For Binary Readouts In Biotech
By:
LifeSciVC
November 5, 2020
July 21, 2024
Read more
Blog
Article
Playing the Long Game for Antibiotic R&D
By:
Timmerman Report
November 5, 2020
July 21, 2024
Read more
Blog
Article
COVID-19 Has Made Hospital Avoidance a Critical Component of Good Care
By:
Nayiri Baljian and Jennifer Reese
August 11, 2020
July 21, 2024
Read more
Blog
Article
SPR720: Listening to Patients, Clinicians and Regulators, and Advancing Forward
By:
Troy Lister, PhD, Sue Stokes, PhD, and David Melnick, MD
June 11, 2020
July 21, 2024
Read more
Blog
Article
BioBoss Podcast with Ankit Mahadevia: CEO of Spero Therapeutics
By:
BioBoss Podcast
April 27, 2020
July 21, 2024
Read more
Blog
Article
Navigating The Unknown: Practical Thoughts On A Team That Can Rise To The Occasion
By:
LifeSciVC
April 2, 2020
July 21, 2024
Read more
Blog
Article
SPR994: A Long Shot, With Lots Of Twists And Turns To Phase III
By:
LifeSciVC
April 2, 2020
July 21, 2024
Read more
Blog
Article
The Balancing Act: Taking A Systematic Approach To Hard Decisions In Times Of Rapid Change
By:
LifeSciVc
April 2, 2020
July 21, 2024
Read more
Blog
Article
Thinking Ahead: Building a Broad Arsenal Against Infectious Disease
By:
Timmerman Report
April 2, 2020
July 21, 2024
Read more
Blog
Article
Evidence Matters: Importance of Tebipenem HBr Oral-Only Trial Design for Clinical Utility and Commercial Uptake Potential
By:
Cristina Larkin and David Melnick, MD
February 26, 2020
July 21, 2024
Read more
Blog
Article
Beyond the headlines: Why we are excited about our pipeline and the future for patients needing effective treatments for infections
By:
Ankit Mahadevia, MD
January 9, 2020
July 21, 2024
Read more
Blog
Article
New Options for Patients: New Preliminary Clinical Data on SPR720 and Our Stepwise Plan to Explore the Broad Potential of SPR720 in NTM
By:
David Melnick, MD
December 6, 2019
July 21, 2024
Read more
Blog
Article
Exciting Independent Review Committee Recommendation Announced Today Based on Positive Interim PK Data from SPR994 ADAPT-PO Phase 3 Clinical Trial
By:
David Melnick, MD
October 3, 2019
July 21, 2024
Read more
Blog
Article
NASDAQ Spotlight Interview of Spero CEO, Ankit Mahadevia, MD
By:
Nasdaq Spotlight
September 25, 2019
July 21, 2024
Read more
Blog
Article
New Strategic Alliances to Build Industry Leading Pipeline: Partnerships with Gates MRI and the Novo REPAIR Impact Fund
By:
Troy Lister
July 2, 2019
July 21, 2024
Read more
Blog
Article
SPR994’s Value Proposition: A dive into how SPR994, an oral carbapenem, could benefit patients, payers, and investors
By:
Joel Sendek
May 15, 2019
July 21, 2024
Read more
Blog
Article
Hiring: Using Your Team To Build A Team
By:
LifeSciVC:
March 12, 2019
July 21, 2024
Read more
Blog
Article
If You Build It, Will They Come? Addressing The Value Equation
By:
LifeSciVC:
March 12, 2019
July 21, 2024
Read more
Blog
Article
Why Are We Losing Oral Antibiotics for the Treatment of cUTI?
By:
Ian Critchley, Ph.D.
March 6, 2019
July 21, 2024
Read more
Blog
Article
Designing the Right Clinical Trial to Yield the Greatest Value
By:
David Melnick, MD and Cristina Larkin
January 4, 2019
July 21, 2024
Read more
Blog
Article
Non-tuberculous Mycobacterial Disease: The Unmet Need and a Possible New Solution with SPR720
By:
Ankit Mahadevia, MD and Cristina Larkin
November 5, 2018
July 21, 2024
Read more
Blog
Article
Boston-area companies bet on antibiotic development, even as big drug makers step back
By:
STAT News:
October 18, 2018
July 21, 2024
Read more
Blog
Article
Meet the BBJ's 2018 40 Under 40 honorees
By:
Boston Business Journal:
October 18, 2018
July 21, 2024
Read more
Blog
Article
Antibiotic Opportunity? Spero's Ankit Mahadevia on The Long Run Podcast
By:
The Timmerman Report:
October 18, 2018
July 21, 2024
Read more
Blog
Article
Investing in Antibiotic Companies: Why the Sector is Compelling Now
By:
Joel Sendek
October 1, 2018
July 21, 2024
Read more
Blog
Article
Spero’s New Inter-agency Collaboration
By:
Ankit Mahadevia
July 16, 2018
July 21, 2024
Read more
Blog
Article
Beyond the CEO: Building An Effective Leadership Team
By:
LifeSciVC
June 10, 2018
July 21, 2024
Read more
Blog
Article
Advancing Spero’s Potentiator Platform
By:
Melissa Stundick, Senior Vice President, Business Development
May 30, 2018
July 21, 2024
Read more
Blog
Article
Billion Dollar Antibiotics in the Era of Stewardship
By:
Cristina Larkin, David Melnick, and Keith A. Rodvold
April 25, 2018
July 21, 2024
Read more
Blog
Article
Antibiotic Drug Development
By:
Ankit Mahadevia, David Melnick, and Paul Ambrose
March 26, 2018
July 21, 2024
Read more
Blog
Article
Biotech startups: What you need to bring your dream to fruition
By:
GoDaddy
January 23, 2018
July 21, 2024
Read more
Blog
Article
Spero Therapeutics Raises $30M Series A, Plans Antibiotic Clinical Trials in 2016
By:
Dow Jones
October 30, 2017
July 21, 2024
Read more
Blog
Article
Spero Completes $30 Million Financing
By:
Marketwatch
October 30, 2017
July 21, 2024
Read more
Blog
Article
Spero Achieves First Milestone Payment in Anti-Infective Partnership with Roche
By:
First Word Pharma
October 30, 2017
July 21, 2024
Read more
Blog
Article
Spero Therapeutics Raised $30M in Series B Funding
By:
Finsmes
October 30, 2017
July 21, 2024
Read more
Blog
Article
Merck & Co. (MRK), New England Patriots Owner Wager $30 Million on Cambridge Startup, Spero
By:
BioSpace
October 30, 2017
July 21, 2024
Read more
Blog
Article
Spero Therapeutics fetches $30 mln Series A
By:
PE Hub
October 30, 2017
July 21, 2024
Read more
Blog
Article
Spero Achieves First Milestone Payment In Anti-Infective Partnership With Roche (RHHBY)
By:
BioSpace
October 30, 2017
July 21, 2024
Read more
Blog
Article
Spero Eyes First Trial, Gets $30M More to Battle Drug-Resistant Bugs
By:
Xconomy
October 28, 2017
July 21, 2024
Read more
Blog
Article
Google Leads $51M Investment in Startup Tackling Drug-Resistant Bacteria
By:
R & D Magazine
October 28, 2017
July 21, 2024
Read more
Blog
Article
Financings
By:
BioWorld Today
October 28, 2017
July 21, 2024
Read more
Blog
Article
Management tracks
By:
BioCentury
October 28, 2017
July 21, 2024
Read more
Blog
Article
Spero Therapeutics Catches Roche’s Eye with a New Way to Target Drug-Resistant Bacterial Infections
By:
MedCity News
October 28, 2017
July 21, 2024
Read more
Blog
Article
Roche returns to antibiotic research as superbug threat grows
By:
Reuters
October 28, 2017
July 21, 2024
Read more
Blog
Article
Antibiotics funding hike gets mixed reception
By:
Nature News and Views
October 28, 2017
July 21, 2024
Read more
Blog
Article
Pushing Forward with Collaborative R&D Models in Biotech
By:
Forbes/LifeSciVC Blog
October 28, 2017
July 21, 2024
Read more
Blog
Article
The Daily Startup: Spero Raises $30M to Fight Drug-Resistant Bacteria
By:
WSJ Venture Capital
October 28, 2017
July 21, 2024
Read more
Blog
Article
News from ASM 2017
By:
BioWorld
October 28, 2017
July 21, 2024
Read more
Blog
Article
Spero Raises $51.7M In Series C
By:
BioCentury
October 28, 2017
July 21, 2024
Read more
Blog
Article
Five things you need to know today, and the value of economic incentives
By:
Boston Business Journal
October 28, 2017
July 21, 2024
Read more
Blog
Article
Building A Stronger Ecosystem to Combat Antimicrobial Resistance
By:
LifeSciVC
October 28, 2017
July 21, 2024
Read more
Blog
Article
The Potentiator: Spero Therapeutics gets $30M to up potency of existing antibiotics
By:
MedCity News
October 28, 2017
July 21, 2024
Read more
Blog
Article
ASM Microbe 2016: Candidate Antimicrobials, Enhancers, Potentiators, Combos Plus New Probe
By:
Microbe Magazine
October 28, 2017
July 21, 2024
Read more
Blog
Article
There’s Big Money Again in Saving Humanity With Antibiotics
By:
Bloomberg
October 28, 2017
July 21, 2024
Read more
Blog
Article
Troy Lister – Bug Battler: Medicinal chemist takes unconventional approach to battling bacteria
By:
Chemical & Engineering News Talented 12
October 28, 2017
July 21, 2024
Read more
Blog
Article
Spero Therapeutics announces $51.7 million in new financing
By:
Boston Globe
October 28, 2017
July 21, 2024
Read more
Blog
Article
Chutes & Ladders
By:
FierceBiotech
October 28, 2017
July 21, 2024
Read more
Blog
Article
Spero Therapeutics raises $30M to support its drug delivery platform targeting Gram-negative bacteria
By:
FierceDrugDelivery
October 28, 2017
July 21, 2024
Read more
Blog
Article
The superbug incentive
By:
The Boston Globe
October 28, 2017
July 21, 2024
Read more
Blog
Article
Roche and Spero Sign Into Antibiotics Partnership
By:
Bioresearch Online
October 28, 2017
July 21, 2024
Read more
Blog
Article
Drug industry warming to antibiotics, but resistance outpaces new products
By:
STAT
October 28, 2017
July 21, 2024
Read more
Blog
Article
Investors Back Bug Fighters
By:
BioWorld Insight
October 28, 2017
July 21, 2024
Read more
Blog
Article
Look Beyond The Headlines: Tackling Ever-Present Challenge Of Antimicrobial Resistance
By:
LifeSciVC.com
October 28, 2017
July 21, 2024
Read more
Blog
Article
News from ECCMID
By:
BioWorld
October 28, 2017
July 21, 2024
Read more
Blog
Article
Biota Pharmaceuticals Sells Antibiotic Program to Spero Therapeutics
By:
Genetic Engineering & Biotechnology News
October 28, 2017
July 21, 2024
Read more
Blog
Article
Spero closes $30M series B round
By:
BioCentury Extra
October 28, 2017
July 21, 2024
Read more
Blog
Article
Execs On The Move, June 2017
By:
In Vivo
October 28, 2017
July 21, 2024
Read more
Blog
Article
Cambridge biotech Spero bags $51M as GV joins latest round
By:
Boston Business Journal
October 28, 2017
July 21, 2024
Read more
Blog
Article
Drug resistance specter fact of life for antibiotics
By:
BioWorld
October 28, 2017
July 21, 2024
Read more
Blog
Article
Spero Emerges with $3M, Backing from Roche, and Plans to Disarm Bugs
By:
Xconomy
October 28, 2017
July 21, 2024
Read more
Blog
Article
Funding, Success for Life Science Startups is On the Rise – Spero Therapeutics
By:
Laboratory Equipment
October 28, 2017
July 21, 2024
Read more
Blog
Article
Dunsire Joins Xtuit to Fight Microenvironment; Spero Gets $51.7M for Antibiotics
By:
Timmerman Report
October 28, 2017
July 21, 2024
Read more
Blog
Article
Can We Save Ourselves From The End Of Antibiotics—Or Have The Superbugs Already Won?
By:
Fast Company Co Exist
October 28, 2017
July 21, 2024
Read more
Blog
Article
Racing toward the right answers: Treating gram-negative bacterial infections
By:
Healio
October 28, 2017
July 21, 2024
Read more
Blog
Article
CARB-X’s first round of grants goes to firms big and small in antimicrobial resistance fight
By:
BioWorld
October 28, 2017
July 21, 2024
Read more
Blog
Article
Atlas startup Spero gets $30M to give new life to old antibiotics
By:
Boston Business Journal
October 28, 2017
July 21, 2024
Read more
Blog
Article
AMPs take aim at AMRs as biopharma seeks new solutions to resistance
By:
BioWorld Insight
October 28, 2017
July 21, 2024
Read more
Blog
Article
Promiliad, Spero Therapeutics, University of Connecticut deal
By:
BioCentury
October 28, 2017
July 21, 2024
Read more
Blog
Article
Growth Phase: Avoiding Vertigo During the Ride Up
By:
LifeSciVC.com
October 28, 2017
July 21, 2024
Read more
Blog
Article
Agencies push bug drug pipeline but development lacks market pull
By:
BioWorld
October 28, 2017
July 21, 2024
Read more
Blog
Article
Meet Spero, a Biotech Hopeful with Roche’s Blessing and a Novel Antiobiotic
By:
FierceBiotech
October 28, 2017
July 21, 2024
Read more
Blog
Article
Atlas Venture’s Newest Stab at an Antibiotics Biotech Comes Out of Stealth
By:
Boston Business Journal
October 28, 2017
July 21, 2024
Read more
Blog
Article
Patriots owner Kraft teams up on a $30M antibiotics round for Spero
By:
FierceBiotech
October 28, 2017
July 21, 2024
Read more
Blog
Article
U.S.–U.K. Alliance Targets World’s Deadliest Superbugs
By:
Managed Care
October 28, 2017
July 21, 2024
Read more
Blog
Article
With $30M, Spero Broadens Fight Against Drug-Resistant Bugs
By:
Xconomy
October 28, 2017
July 21, 2024
Read more
Blog
Article
Startup Spero Makes Antibiotics Pact with Roche
By:
GEN News
October 28, 2017
July 21, 2024
Read more
Blog
Article
Spero Therapeutics Licenses Dihydrofolate Reductase Inhibitors from Promiliad Biopharma
By:
BioWorld Today
October 28, 2017
July 21, 2024
Read more
Blog
Article
Spero shoots through series C target
By:
Global University Venturing
October 28, 2017
July 21, 2024
Read more
Blog
Article
Spero pads syndicate, lands $51.7M series C for pipeline of antibacterials
By:
BioWorld Today
October 28, 2017
July 21, 2024
Read more
Blog
Article
Glaxo, Atlas syndicate bankrolls Spero’s drive into the clinic with $30M round
By:
FierceBiotech
October 28, 2017
July 21, 2024
Read more
Blog
Article
China rises as a biotech powerhouse, developing drugs to treat the world
By:
STAT
October 28, 2017
July 21, 2024
Read more
Blog
Article
Google’s venture arm leads Spero’s $51.7M round for R&D work on a pipeline of new antibiotics
By:
Endpoints
October 28, 2017
July 21, 2024
Read more
Blog
Article
Google’s Venture Arm Leads $51.7M Investment in Spero Therapeutics
By:
Xconomy
October 28, 2017
July 21, 2024
Read more
Blog
Article
Merck, New England Patriots Boss Bet $30M On Antibiotics Startup Spero
By:
Forbes
October 28, 2017
July 21, 2024
Read more